

# *Metabonomics-based analysis of Brachyspira pilosicoli's response to tiamulin reveals metabolic activity despite significant growth inhibition*

Article

Accepted Version

Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0

Le Roy, C. I., Passey, J. L., Woodward, M. J., La Ragione, R. M. and Claus, S. P. (2017) Metabonomics-based analysis of Brachyspira pilosicoli's response to tiamulin reveals metabolic activity despite significant growth inhibition. Anaerobe, 45. pp. 71-77. ISSN 1075-9964 doi: 10.1016/j.anaerobe.2017.03.018 Available at <https://centaur.reading.ac.uk/70003/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

Published version at: <http://www.sciencedirect.com/science/article/pii/S1075996417300677>

To link to this article DOI: <http://dx.doi.org/10.1016/j.anaerobe.2017.03.018>

Publisher: Elsevier

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the [End User Agreement](#).

[www.reading.ac.uk/centaur](http://www.reading.ac.uk/centaur)

## **CentAUR**

Central Archive at the University of Reading

Reading's research outputs online

**Metabonomics-based analysis of *Brachyspira pilosicoli*'s response to tiamulin reveals metabolic activity despite significant growth inhibition.**

Caroline Ivanne Le Roy<sup>a,b</sup>, Jade Louise Passey<sup>c</sup>, Martin John Woodward<sup>a</sup>, Roberto Marcello La Ragione<sup>c</sup>, Sandrine Paule Claus<sup>a#</sup>.

<sup>a</sup> Department of Food and Nutritional Sciences, University of Reading, Whiteknights, Reading, UK6 6AP, UK

Present address <sup>b</sup> Department of Twin Research & Genetic Epidemiology, King's College London, London SE1 7EH, UK

<sup>c</sup> Faculty of Health and Medical Sciences, School of Veterinary Medicine, University of Surrey, Guilford, Surrey GU2 7XH, UK

# Corresponding author: [s.p.claus@reading.ac.uk](mailto:s.p.claus@reading.ac.uk), Tel +44 118 378 8717

**Key words: Metabonomics, *Brachyspira pilosicoli*, Tiamulin, Antibiotics.**

**Abstract**

Pathogenic anaerobes *Brachyspira spp.* are responsible for an increasing number of Intestinal Spirochaetosis (IS) cases in livestock against which few approved treatments are available. Tiamulin is used to treat swine dysentery caused by *Brachyspira spp.* and recently has been used to handle avian intestinal spirochaetosis (AIS). The therapeutic dose used in chickens requires further evaluation since cases of bacterial resistance to tiamulin have been reported. In this study, we evaluated the impact of tiamulin at varying concentrations on the metabolism of *B. pilosicoli* using a <sup>1</sup>H-NMR-based

metabonomics approach allowing the capture of the overall bacterial metabolic response to antibiotic treatment. Based on growth curve studies, tiamulin impacted bacterial growth even at very low concentration (0.008 µg/ml) although its metabolic activity was barely affected 72 h post exposure to antibiotic treatment. Only the highest dose of tiamulin tested (0.250 µg/ml) caused a major metabolic shift. Results showed that below this concentration, bacteria could maintain a normal metabolic trajectory despite significant growth inhibition by the antibiotic, which may contribute to disease reemergence post antibiotic treatment. Indeed, we confirmed that *B. pilosicoli* remained viable even after exposition to the highest antibiotic dose. This paper stresses the need to ensure new evaluation of bacterial viability post bacteriostatic exposure such as tiamulin to guarantee treatment efficacy and decrease antibiotic resistance development.

## Highlight

- *B. pilosicoli* metabolism was characterized using <sup>1</sup>H NMR-based metabonomics
- Tiamulin inhibited *B. pilosicoli* growth at very low dose (respectively < 0.016 µg/mL and > 0.032 µg/mL)
- *B. pilosicoli* metabolism is not inhibited for tiamulin concentration superior to 0.032 µg/mL
- *B. pilosicoli* metabolism is completely repressed at 0.250 µg/mL, but remain viable

## 1. Introduction

*Brachyspira pilosicoli* is a gram-negative bacterium of the Spirochaetes family. It colonizes the lower part of the gastrointestinal track of a large range of hosts including

pigs, birds, humans, monkeys, dogs and horses [1-4]. Once in the intestinal lumen, the bacterium is attracted *via* chemotaxis to the mucin barrier [5,6] through which it swims mediated by its unique “corkscrew” shape and rotation of its periplasmic flagella [7] aided by the secretion of mucine degrading enzymes [5,8]. *B. pilosicoli* attaches to the enterocytes in an end on fashion and may also infect these cells [9-12]. Colonization by *B. pilosicoli* can lead to the development of intestinal spirochaetosis (IS), the signs of which are diarrhea, poor overall condition, dehydration and decreased growth rate. Mortality is often significant when the disease is left untreated [13-15], a consequence that makes IS a serious economic and welfare problem in farming.

Tiamulin is effective in treating IS caused by *Brachyspira hyodystenteriae*, *B. hampsonii* and *B. pilosicoli* in swine [16-18] and in poultry [19-21]. Tiamulin is a bacteriostatic derived from a natural pleuromutilin that binds the 50S region of the ribosome to inhibit protein synthesis [22]. The antibiotic blocks peptide bond formation by interfering with substrate binding [22-25]. Tiamulin treatment in farms generally results in clearance of infection and associated symptoms. However, reoccurrence of the disease can be observed post treatment indicating incomplete clearance and possibly decreased susceptibility [26,27] in response to treatment. The reason may be an inappropriate dosing as there is currently there is a lack of an internationally recognized standardized method to determine tiamulin minimum inhibitory concentration (MIC) for this bacterium, which has impacts upon selection of an appropriate treatment dose. Furthermore, recent studies have indicated that *Brachyspira* may acquire resistance against tiamulin and, other than blocking protein synthesis, nothing is yet known of the metabolic response of *B. pilosicoli* to tiamulin. We argue that evaluating this using a metabonomics approach would allow a better

understanding of the bacterial response to tiamulin and give insights into improving selection of effective dosing regimes.

Metabonomics allows non-targeted evaluation of the metabolic modifications occurring in a biological system in response to a stress [28], which in this study is exposure to tiamulin. By providing a general overview of the metabolic response, this technique allows the generation of new hypotheses and to evaluate metabolic in response to environmental stress or genetic modification. In this study, we used an NMR-based metabonomics approach coupled with multivariate statistics to evaluate the metabolic dose-response of *B. pilosicoli* to tiamulin. Bacteria were exposed to gradual antibiotic doses and media were sampled over 120h in order to evaluate the evolution of its metabolic composition during growth. This allowed to snapshot the metabolic response of *B. pilosicoli* to tiamulin.

## 2. Material and Methods

### 2.1. Bacterial growth and antibiotic assay

*B. pilosicoli* B2904 isolated from chicken presenting clinical signs of AIS in the UK [29] were grown from frozen stock on agar solidified BEB plate for four days under anaerobic conditions (94% N<sub>2</sub> and 6% CO<sub>2</sub>) at 37°C. Colonies were transferred into *Brachyspira* enrichment broth media (BEB supplemented with heart infusion) for three days under similar conditions. The bacterial concentration was then adjusted in BEB to 1 x 10<sup>6</sup> CFU/ml and transferred into 24 well plates (2 ml per well) and incubated as above for 120h. Every 24 h (with a first time point at 0 h growth), the entire well content was taken and centrifuged for 2 min at 2400 g to separate growth medium from bacteria. The supernatant was kept at - 80°C for further analysis. This process was

repeated at each time point in sextuplet to deliver the appropriate power for statistical analysis.

The same method was used for the tiamulin assay. Bacterial cells were grown as above and bacterial pellets were resuspended in BEB with antibiotic at six concentrations (0.008, 0.016, 0.031, 0.062, 0.125 and 0.250 µg/ml plus control). Bacteria were then inoculated into 24 well plates as previously described and incubated for 120h. For metabolic analysis, each condition (tiamulin concentration) and time point (every 24 h for 120 h) were also repeated in sextuplet. The medium was not changed for the duration of the experiment so that antibiotic exposure was continuous.

To evaluate the viability of *B. pilosicoli* post- antibiotic exposure, the above experiment was repeated in triplicate. Following 120 h incubation, *B. pilosicoli* was inoculated onto fastidious anaerobic blood agar and incubated at 37°C, anaerobically for 48 h. Following incubation all plates were visually inspected for bacterial growth.

*B. pilosicoli* growth was evaluated using the same experimental design as the one previously described. Bacteria were grown in a 96 well plate (0.2 ml per well) and bacterial growth was evaluated every 2 h for 120 h at an absorbance of 600 nm using a Fluostar (Info). Water was used as blank and broth media without bacteria as a negative control. Each condition (tiamulin concentration) was repeated in triplicate and results are presented as an average of the log of the bacterial concentration calculated from the absorbance observed at each tiamulin concentration per time point after correction with standard curve.

## 2.2. NMR spectroscopy

For NMR spectroscopy, 0.4 ml of media was added to 0.2 ml of NMR phosphate buffer (made in D<sub>2</sub>O containing 10 % water and 0.05 % sodium 3-(tri-methylsilyl) propionate-

2,2,3,3-d<sub>4</sub> (TSP) as a <sup>1</sup>H NMR reference) and 0.5 ml of the solution was transferred into 5 mm of outer diameter NMR tubes. <sup>1</sup>H-NMR spectra were acquired on a Bruker Avance DRX 700 MHz NMR Spectrometer (Bruker Biopsin, Rheinstetten, Germany) operating at 700.19 MHz and equipped with a cryogenic probe from the same manufacturer. A standard 1-dimensional (1D) pulse sequence [recycle delay (RD)-90°-*t*<sub>1</sub>-90°-*tm*-90°-acquire free induction decay (FID)] with water suppression applied during RD of 2 s and a mixing time (*tm*) of 100 ms and a 90° pulse set at 10 μs was applied. For each spectrum 128 scans were recorded on a total of 32K data points. A broadening line function of 0.3 Hz was used to multiply all FIDs. After acquisition, all spectra were manually phased and baseline corrected using the software MestReNova® (version 2.1.8-11880, MestreLab, Spain). Finally, spectra were calibrated to the chemical shift of TSP (δ 0.00). In order to facilitate metabolite identification based on literature, a series of 2D spectra on selected samples were acquired using correlation spectroscopy (COSY) NMR spectroscopy.

### 3.3. Statistical analysis

All spectra were scaled on unit variance and mean centered prior to analysis. To evaluate metabolic variation between samples, principal component analysis (PCA) was used. Orthogonal projection to latent structure discriminant analysis (O-PLS-DA) was also performed, where <sup>1</sup>H-NMR spectra were used as a matrix of independent variables (X) and time or antibiotic concentration were used as prediction vectors (Y) to capture the metabolic variations linear to time and antibiotic concentration. O-PLS DA models were generated between each tiamulin concentration at every time point independently. A heat map was generated using each of this model strength in order to



visualize when tiamulin impacted bacterial metabolism in comparison to control and if clusters related to dose could be observed.

### 3. Results

#### 3.1. Modifications of *B. pilosicoli* metabolism during growth

The aim of this study was to characterize *B. pilosicoli* metabolism under optimum growth conditions. Figure 1 presents *B. pilosicoli* growth and metabolic activity in broth media. PC1, which captured 49% of the metabolic variation, indicated that a significant metabolic shift was recorded after 96 h of incubation. Distinctions between 0 h, 24 h and 48 h were observed on the 3rd component, representing only 9% of the total variation, which suggests a modest effect on the composition of the culture medium over the first 48 h. This metabolic trajectory indicates that bacterial metabolism might change depending on the growth phase (Figure 1A and B). Scores from the same time point were clustered together indicating good reproducibility of the experiment.

In the antibiotic free culture medium, the growth of *B. pilosicoli* was associated with a decrease in glucose and an increase in amino acids (phenylalanine, alanine, tyrosine, lysine, valine and methionine), fermentation products (lactate, acetate, butyrate and isovalerate), as well as other compounds involved in the regulation of cell osmosis such as *myo*-inositol and trimethylamine (TMA) as observed in the PCA results presented in Figures 1A and C.

Glucose was the only readily identifiable substrate that showed a reduction over time (Figure 1C). Decreased concentration of other substrates could not be detected and it is possible that some may be below the detection limit of the NMR instrument. Nevertheless, it is not unreasonable to assume that glucose was the only carbon source used for bacterial anabolism and growth. *B. pilosicoli* and more especially the strain

used for this experiment (B2904) is able to use a wide range of carbohydrates and hexoses as primary carbon sources [10] but it would seem in this study that glucose was used preferentially.

### 3.2. Tiamulin impacts *B. pilosicoli* growth even at very low doses

Having characterized the metabolic footprint of *B. pilosicoli* when grown in optimal conditions, we then challenged it with increasing tiamulin doses. Tiamulin impacted *B. pilosicoli*'s growth at the lowest concentrations tested (0.008 and 0.016 µg/mL) as displayed in Figure 2. For these two doses, the bacterial count observed at the stationary phase was one log lower than for the control demonstrating the ability of tiamulin to reduce the growth of *B. pilosicoli* at low concentrations. Up to 54 hours, growth curves of the two lowest concentrations (0.008 and 0.016 µg/mL) were identical to the control (T1 and T2 on the graph) but they stopped growing shortly after and entered into the stationery phase. No bacterial growth was detected for higher tiamulin concentrations (over 0.032 µg/mL) confirming its efficiency to stop bacterial proliferation. Interestingly, no gradual tiamulin dose response of bacterial growth was observed. Indeed, growth rates were similar for the two lowest concentrations (0.008 and 0.016 µg/mL) while higher doses induced a complete inhibition of *B. pilosicoli*'s growth.

### 3.3. Metabolic response of *B. pilosicoli* to tiamulin

A clear metabolic response of *B. pilosicoli* to tiamulin could be observed when the antibiotic dose exceeded to 0.032 µg/mL. At lower doses (0.008 and 0.016 µg/mL), although *B. pilosicoli* growth was decreased by 1 log (Figure 2) compared with

untreated control, the metabolic trajectories remained unaffected (Figure 3A, Supplemental Fig.1 and 2).

When bacteria were exposed to 0.032  $\mu\text{g/mL}$  of tiamulin (Supplemental Fig. 3), a disruption of the metabolic trajectory was observed which was due to modifications of amino acid concentration. A noticeable increase of tyrosine, methionine, valine, phenylalanine and lysine into the medium from 0 to 96 h was observed. After that time, their concentration reduced, indicating consumption of these amino acids until the end of the experiment. After 120h of growth, the metabolic composition of the media was comparable to control, indicating the full recovery of the metabolism following antibiotic exposure.

Higher doses of tiamulin (0.062 and 0.125  $\mu\text{g/mL}$ ) induced similar responses to those observed at 0.032  $\mu\text{g/mL}$  (Figure 3A and Supplemental Fig. 4. A and B). Amino acid metabolism was affected in a greater extent.

At the maximum dose tested (0.250  $\mu\text{g/mL}$ ) the metabolic trajectory observed for the media was drastically modified in comparison to those described previously (Figure 3 and Supplemental Fig. 5). The metabolic trajectory followed a circular shape where the scores of the samples collected after 120h of bacterial growth were clustered with the ones observed at T0, indicating metabolic similarities with the baseline time-point. Once again, amino acids were released into the medium as well as butyrate and *myo*-inositol.

#### 3.4. *B. pilosicoli* survives post-antibiotic exposure

To evaluate the surviving potential of *B. pilosicoli* after tiamulin exposure, samples from replication of the growth curve experiment were plated on agar plate at the end of the antibiotic challenge (120 h). For all tiamulin doses applied it was possible to observe *B.*

*pilosicoli* colony formation on agar plates (Supplement Table 1). These results indicate that *B. pilosicoli* is able to recover from tiamulin exposure (even at the highest dose of 0.250 µg/mL) once back in optimal growth conditions.

#### 4. Discussion

The results obtained from *B. pilosicoli* growth in a control medium without tiamulin provide new insights about its general metabolism. The bacteria were able to produce lactate and acetate from glucose fermentation without secreting methanol, suggesting the use of the bifidum pathway according to the following equation: glucose → 3 acetate + 2 lactate [30]. However, lactate was generally found in very small quantity in comparison to acetate, indicating its potential use in other metabolic reactions. Bacteria were also able to secrete butyric acid but not propionic acid. Both of these short chain fatty acids were found to be potential carbon sources for *B. pilosicoli* [10]. Bacteria also released a large number of amino acids that could be caused either by synthesis and active secretion of these amino acids, or more likely due to exogenous protein degradation. This result is in accordance with the genetic results published by Mappley et al. [10] that indicated a strong proteolytic capacity of the bacterium. This specific strain of *B. pilosicoli* was also shown to be able to use amino acids as primary carbon source [10]. However, as the bacterium favors glucose if available as primary carbon source, amino acids may here only be used for protein synthesis and may therefore become in excess in the culture medium where they accumulate. Finally, the bacteria secreted TMA. Gut bacteria generally produce TMA from dietary L-carnitine, betaine or choline. Yet, it was not possible to detect a decrease in concentration of these compounds indicating that *B. pilosicoli* might not use these molecules as precursors or that the technique used was not sensitive enough to detect such variations.

More importantly, this work confirmed tiamulin ability to significantly reduce at very low doses (0.008 and 0.016  $\mu\text{g/mL}$ ) and inhibit at higher concentrations *B. pilosicoli* growth. Decreased growth rate at such low antibiotic doses were unexpected, as previous evaluation of minimum inhibitory concentration (MIC) values for this specific strain were of 0.250  $\mu\text{g/mL}$  [31], furthermore, 10-15% of *B. pilosicoli* isolates presented MICs > 4  $\mu\text{g/mL}$  [31]. Differences in the MIC values can be explained by experimental conditions. Growth curves were acquired when *B. pilosicoli* was grown in BEB media rather than on agar plates for MIC tests. The *B. pilosicoli* strain B2904 used in this study is known to have an MIC of 0.250  $\mu\text{g/mL}$  [31,32] but showed clear inhibition of growth with concentrations below this value. Thus, our findings confirm the previously reported observation that lower tiamulin MIC values are generally found in broth compared to agar for *B. hyodysenteriae* [33].

Despite these encouraging results regarding tiamulin efficiency to inhibit pathogen growth, the evaluation of *B. pilosicoli* metabolic viability in response to antibiotic treatment revealed that classic MIC calculations might not be sufficient to assess antibiotic efficiency. Indeed, *B. pilosicoli* metabolic rate reduction did not mirror previously commented reduced growth rate in response to tiamulin treatment. At the two lowest doses used (0.008 and 0.016  $\mu\text{g/mL}$ ), *B. pilosicoli* growth was reduced by one log in comparison to control. However, the metabolic trajectories observed by the media were identical. Indicating that tiamulin was able to impact growth but that *B. pilosicoli* basic metabolism remained unaffected. Higher doses were able to reduce but not silent *B. pilosicoli* metabolism despite complete growth inhibition. Furthermore, the metabolism of *B. pilosicoli* appears to slightly recover from all tiamulin concentrations except from 0.250  $\mu\text{g/mL}$  after 120 h of growth. This might be due to the apparition of resistance, which is known as being a slow bacterial development process [34,35].

270 In addition, it was demonstrated that *B. pilosicoli* was able to survive post-tiamulin  
271 exposure even at the highest antibiotic dose when plated on agar (after 120 h drug  
272 exposure). Indeed *B. pilosicoli* colonies were identified 48h after the end of the  
273 antibiotic treatment for all doses tested (0.008-0.250 µg/mL). These results illustrate  
274 the potential of *B. pilosicoli* to enter a dormancy state when exposed to tiamulin that is  
275 reversible once the treatment period is over.

276 Besides, results demonstrated a slow response of the bacteria to antibiotic treatment as  
277 modification of the metabolic footprint was only observed after more than 48 h of  
278 growth in presence of tiamulin. From these results, it seems that metabolism was  
279 stressed during the exponential phase, when bacterial division is compromised.  
280 Metabolism modification was mainly associated with increased amino acid  
281 consumption (that were produced in the control). However, as the provenance of these  
282 amino acids remains unclear, two hypotheses can be formulated. Firstly, in response to  
283 antibiotic stress bacteria could use amino acids as alternative energy substrates.  
284 Secondly, *B. pilosicoli* might not be able to hydrolyse proteins present in the media  
285 because new protein synthesis, such as secreted proteases, is blocked at the ribosome.  
286 The specificity of the amino acids used indicates the first option is the most probable  
287 and that catabolism repression could be overridden to secure energy from multiple  
288 sources. This is an interesting hypothesis that needs confirmation by alternative  
289 techniques such as transcriptomics.

290 The fact that *B. pilosicoli* remain viable and metabolically active without dividing despite  
291 the antibiotic treatment and is able to recover after antibiotic exposure could partly  
292 explain the IS relapse observed in farms after tiamulin intervention. Indeed, it seems to  
293 arise from these results that bacteria remain viable but are not able to divide entering  
294 therefore a dormancy stage. It is highly possible that such phenomenon occurs in the

intestinal lumen, where bacteria could suffer from inactivation of cell division but remain viable. This bacterial state might be associated with a decrease in their pathogenicity explaining the disappearance of associated symptoms. Nevertheless, bacteria might remain viable but at a “dormancy” state in the intestinal lumen or animal faeces until the environment becomes less hostile (end of antibiotic treatment) when they can recover their pathogenic property. However, it is impotent to point out that here *B. pilosicoli* was recovered on agar plates that represent optimal growth conditions. This might not be the case in the intestinal lumen that is a more hostile environment when the bacterium also needs to compete with other commensal bacteria and is confronted to the host’s immune system.

As increasing antibiotic resistance mechanisms developed by pathogenic bacteria are arising, many studies and reviews have stressed the concerns linked to inappropriate antibiotic usage. Indeed, this is strongly linked to development of antibiotic resistance, a burden for health and industry. There is therefore a surge for redefining appropriate antibiotic use that would help minimizing the current concern linked to decreased antibiotic efficiency. Thus, importance should be given to new methods development aiming at better assessing antibiotic efficiency and to detect potential antibiotic resistance factor development. This study indicates that metabonomics could be an easy and practical way to evaluate bacterial metabolic activity and therefore assess antibiotic efficiency to totally inactivate pathogens and therefore avoid infection relapse.

## **5. Conclusion**

This work gave a clearer understanding of *B. pilosicoli* metabolism in optimum growth conditions, including indication regarding favored fermentation pathways and amino

acids metabolism. It supports the fact that tiamulin can inhibit efficiently bacterial growth at low concentrations. However, it was surprising to observe that tiamulin could impact *B. pilosicoli* growth without influencing its basic metabolism. It also reveals that the bacterium try to maintain metabolic homeostasis despite an obvious stress visible on the growth curve, demonstrating that in response to xenobiotic stress, bacterial division is the first mechanism to be suspended. This indicates that tiamulin might present a good solution against AIS outbreaks, as it is able to significantly reduce or stop bacterial growth, provided that the efficient dose is achieved in the gut of every individual. Even so, the treatment may not be sufficient to avoid relapse of the disease. Such findings suggest that measurement of bacterial activity might be needed in order to assess antibiotic efficiency against potential reoccurrence of the disease. In that prospect, metabonomics appeared as a potential solution to evaluate if antibiotic treatment can inactivate microbial metabolic activity.

## References

- [1] Stanton, T. B. & Hampson, D. J. Physiology of Ruminant and intestinal spirochaetes. *CAB Int.* 7–45 (1997).
- [2] Duhamel, G. E., Stryker, C. J., Lu, G., Wong, V. J. & Tarara, R. P. Colonic spirochetosis of colony-raised rhesus macaques associated with *Brachyspira* and *Helicobacter*. *Anaerobe*. **9**, 45–55 (2003).
- [3] Hidalgo, A., Rubio, P., Osorio, J. & Carvajal, A. Prevalence of *Brachyspira pilosicoli* and '*Brachyspira canis*' in dogs and their association with diarrhoea. *Vet. Microbiol.* **146**, 356–60 (2010).
- [4] Trott, D. J., Stanton, T. B., Jensen, N. S., Duhamel, G. E., Johnson, J. L., & Hampson, D. J. *Serpulina pilosicoli* sp., the agent of porcine intestinal spirochetosis. *Int. J. Syst. Bacteriol.* **46**, 206–15 (1996).
- [5] Naresh, R. & Hampson, D. J. Attraction of *Brachyspira pilosicoli* to mucin. *Microbiology*. **156**, 191–7 (2010).
- [6] Hopwood, D., Pethick, D. & Hampson, D. Increasing the viscosity of the intestinal



349 contents stimulates proliferation of enterotoxigenic *Escherichia coli* and  
350 *Brachyspira pilosicoli* in weaner pigs. *Br. J. Nutrition*. **88**, 523–532 (2007).

351 [7] Prapasarakul, N., Lugsomya, K., Disatian, S., Lekdumrongsak, T., Banlunara, W.,  
352 Chetanachan, P., & Hampson, D. J. Faecal excretion of intestinal spirochaetes by  
353 urban dogs, and their pathogenicity in a chick model of intestinal spirochaetosis.  
354 *Res. Vet. Sci.* **91**, e38–43 (2011).

355 [8] Li, C., Motaleb, A., Sal, M., Goldstein, S. F. & Charon, N. W. Spirochete periplasmic  
356 flagella and motility. *J. Mol. Microbiol. Biotechnol.* **2**, 345–54 (2000).

357 [9] Dworkin, M. *The prokaryotes: Vol. 7: Proteobacteria: Delta and Epsilon Subclasses*.  
358 S. Falkow, E. Rosenberg, K. H. Schleifer, & E. Stackebrandt (Eds.). Springer Science  
359 & Business Media. 2006.

360 [10] Mappley, L. J., Black, M. L., AbuOun, M., Darby, A. C., Woodward, M. J., Parkhill, J.,  
361 Turner, A. K., Bellgard, M. I., La, T., Philips, N. D., La Ragione, R. M. & Hampson, D.  
362 J. Comparative genomics of *Brachyspira pilosicoli* strains: genome  
363 rearrangements, reductions and correlation of genetic compliment with  
364 phenotypic diversity. *BMC Genomics*. **13**, 454 (2012).

365 [11] Dassanayake, R. P. Biochemical properties of membrane-associated proteases of  
366 *Brachyspira pilosicoli* isolated from humans with intestinal disorders. *J. Med.*  
367 *Microbiol.* **53**, 319–323 (2004).

368 [12] Nakamura, S., Adachi, Y., Goto, T. & Magariyama, Y. Improvement in Motion  
369 Efficiency of the Spirochete *Brachyspira pilosicoli*. *Biophys. J.* **90**, 3019–3029  
370 (2006).

371 [13] Fellström, C. & Gunnarsson, A. Phenotypical characterisation of intestinal  
372 spirochaetes isolated from pigs. *Res. Vet. Sci.* **59**, 1–4 (1995).

373 [14] Duhamel, G. E., Hunsaker, B. D., Mathiesen, M. R., & Moxley, R. A. Intestinal  
374 spirochaetosis and giardiasis in a beagle pup with diarrhoea. *Vet. Pathol.* **33**, 360-  
375 362 (1996)

376 [15] Taylor, D. J., Simmons, J. R. & Laird, H. M. Production of diarrhoea and dysentery in  
377 pigs by feeding pure cultures of spirochaete differing from *Treponemu*  
378 *hyodysenteriae*. *Vet.* **106**, 326–332 (1980).

379 [16] Johnston, W. T., Dewey, C. E., Friendship, R. M., Smart, N., McEwen, B. J., Stalker,  
380 M., & de Lange, C. F. An investigation of the etiology of a mild diarrhea observed in  
381 a group of grower/finisher pigs. *Can. Vet. J.* **42**, 33–37 (2001).

382 [17] Wilberts, B. L., Arruda, P. H., Warneke, H. L., Erlandson, K. R., Hammer, J. M., &  
383 Burrough, E. R. Cessation of clinical disease and spirochete shedding after  
384 tiamulin treatment in pigs experimentally infected with '*Brachyspira hampsonii*'.

385        *Res. Vet. Sci.* **97**, 341–347 (2014).

386    [18] Burch, D. Tiamulin activity against *Brachyspira hyodysenteriae*. *Vet. Rec.* **163**, 698  
387        (2008).

388    [19] Burch, D. & Klein, U. Treatment of *Brachyspira* species with high MICs against  
389        Tiamulin in layers. *6th Int. Conf. Avian Intest. Spirochaetosis Infect. Anim. Humans.*  
390        51 (2013).

391    [20] Stephens, C. P. & Hampson, D. J. Evaluation of tiamulin and lincomycin for the  
392        treatment of broiler breeders experimentally infected with the intestinal  
393        spirochaete *Brachyspira pilosicoli*. *Avian Pathol.* **31**, 299–304 (2002).

394    [21] Burch, D. G. S., Harding, C., Alvarez, R. & Valks, M. Treatment of a field case of  
395        avian intestinal spirochaetosis caused by *Brachyspira pilosicoli* with tiamulin.  
396        *Avian Pathol.* **35**, 211–6 (2006).

397    [22] Schlünzen, F., Pyetan, E., Fucini, P., Yonath, A. & Harms, J. M. Inhibition of peptide  
398        bond formation by pleuromutilins: the structure of the 50S ribosomal subunit  
399        from *Deinococcus radiodurans* in complex with tiamulin. *Mol. Microbiol.* **54**, 1287–  
400        1294 (2004).

401    [23] Poulsen, S. M., Karlsson, M., Johansson, L. B., & Vester, B. The pleuromutilin drugs  
402        tiamulin and valnemulin bind to the RNA at the peptidyl transferase centre on the  
403        ribosome. *Mol. Microbiol.* **41**, 1091–1099 (2001).

404    [24] Long, K. S., Hansen, L. H., Jakobsen, L. & Vester, B. Interaction of pleuromutilin  
405        derivatives with the ribosomal peptidyl transferase center. *Antimicrob. Agents*  
406        *Chemother.* **50**, 1458–1462 (2006).

407    [25] Forschungsinstitut, S. The Mode of action of pleuromutilin derivatives effect on  
408        cell-free polypeptide synthesis. *Europ. J. Biochem.* **533**, 527–533 (1974).

409    [26] Stephens, C. P. & Hampson, D. J. Evaluation of tiamulin and lincomycin for the  
410        treatment of broiler breeders experimentally infected with the intestinal  
411        spirochaete *Brachyspira pilosicoli*. *Avian Pathol.* **31**, 299–304 (2002).

412    [27] Burch, D. G. S., Harding, C., Alvarez, R. & Valks, M. Treatment of a field case of  
413        avian intestinal spirochaetosis caused by *Brachyspira pilosicoli* with tiamulin.  
414        *Avian Pathol.* **35**, 211–6 (2006).

415    [28] Sperling, D., Smola, J. & Cízek, A. Characterisation of multiresistant *Brachyspira*  
416        *hyodysenteriae* isolates from Czech pig farms. *Vet. Rec.* **168**, 215 (2011).

417    [29] Karlsson, M., Aspan, A., Landén, A., & Franklin, A. Further characterization of  
418        porcine *Brachyspira hyodysenteriae* isolates with decreased susceptibility to  
419        tiamulin. *J. Med. Microbiol.* **53**, 281–285 (2004).

420    [30] Nicholson, J. K., Lindon, J. C. & Holmes, E. ‘Metabonomics’: understanding the

metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. *Xenobiotica*. **29**, 1181–9 (1999).

[31] Mappley, L. J., Tchórzewska, M. a, Cooley, W. a, Woodward, M. J. & La Ragione, R. M. Lactobacilli antagonize the growth, motility, and adherence of *Brachyspira pilosicoli*: a potential intervention against avian intestinal spirochetosis. *Appl. Environ. Microbiol.* **77**, 5402–5411 (2011).

[32] Gottschalk, G. *Bacterial metabolism*. Springer Science & Business Media. (2012).

[33] Pringle, M., Landén, A., Unnerstad, H. E., Molander, B. & Bengtsson, B. Antimicrobial susceptibility of porcine *Brachyspira hyodysenteriae* and *Brachyspira pilosicoli* isolated in Sweden between 1990 and 2010. *Acta Vet. Scand.* **54**, 54 (2012).

[34] Woodward, M. J., Mappley, L., Le Roy, C., Claus, S. P., Davies, P., Thompson, G., & La Ragione, R. M. Drinking water application of Denagard® Tiamulin for control of *Brachyspira pilosicoli* infection of laying poultry. *Res. Vet. Sci.* **103**, 87–95 (2015).

[35] Rohde, J., Kessler, M., Baums, C. G. & Amtsberg, G. Comparison of methods for antimicrobial susceptibility testing and MIC values for pleuromutilin drugs for *Brachyspira hyodysenteriae* isolated in Germany. *Vet. Microbiol.* **102**, 25–32 (2004).

[36] Bock, A., Turnowsky, F., Hogenauer, G., Universitat, M. D. & Germany, W. Tiamulin resistance mutations in *Escherichia coli*. *J. Bacteriol.* **151**, 1253–1260 (1982).

[37] Karlsson, M., Gunnarsson, A. & Franklin, A. Susceptibility to pleuromutilins in *Brachyspira (Serpulina) hyodysenteriae*. *Anim. Heal. Res. Rev.* **2**, 59–66 (2001).

## Figures and tables

Figure 1: *B. pilosicoli* consumed glucose and released amino acids and fermentation products in its environment. (A) PCA scores plot. (B) *B. pilosicoli* growth curve in *Brachyspira* enrichment broth media under anaerobic conditions made in triplicate. (C) Associated loadings of the first component. The metabolic trajectories described by the arrows were determined by the position of the centroids calculated at each time point using the coordinate of the associated scores on the principal components.

Figure 2: Impact of tiamulin on *B. pilosicoli* growth in *Brachyspira* enrichment broth media under anaerobic conditions. Growth was measured in triplicate every 2 h for 120 h.

Figure 3: (A) Metabolic trajectories derived from the PCA analysis performed using all the sample population (N=252) of the study (i.e. control plus 6 tiamulin dilution) on PC1 and PC3 displaying the centroids for each time points of the control and three concentrations of tiamulin. (B) Heat map representing the O-PLS DA model strength existing between each tiamulin concentration at each time point, based on R<sup>2</sup>Y (goodness of fit of the model) and Q<sup>2</sup>Y (goodness of prediction of the model) values using the following formula:  $Model\ strength = \frac{R^2Y \times Q^2Y}{R^2Y - Q^2Y}$ .

## Supplemental material

Supplement Fig. 1: Metabolic trajectories of *B. pilosicoli* footprints in broth media for 120 h at a tiamulin concentration of: 0.008 µg/mL (A) and 0.016 µg/mL (B). The arrows indicate the metabolic trajectory. The metabolic trajectories described by the arrows were determined by the position of the centroids calculated at each time point using the coordinate of the associated scores on the PCs.

Supplement Fig. 2: Metabolic variation related to PCA scores plots presented in Supplement Fig. 1. (A) loadings of the principal component 1 of the model presented in Fig A.1.A. (B) loadings of the principal component 3 of the model presented in

Supplement Fig. 1.A. (C) loadings of the principal component 1 of the model presented in Supplement Fig. 1.B. (D) loadings of the principal component 4 of the model presented in Supplement Fig. 1.B.

Supplement Fig. 3: Metabolic trajectories of *B. pilosicoli* footprint in broth media for 120 h at a tiamulin concentration of 0.032 µg/ml on principal component 1 and 3. (A) PCA score plot. (B) Associated loading plot for PC1. The metabolic trajectories described by the arrows were determined by the position of the centroids calculated at each time point using the coordinate of the associated scores on the PCs.

Supplement Fig. 4: Metabolic trajectories of *B. pilosicoli* footprint in broth media for 120 h at a tiamulin concentration of: 0.062 µg/ml (A) and 0.125 µg/ml (B). The arrows indicate the metabolic trajectory. The metabolic trajectories described by the arrows were determined by the position of the centroids calculated at each time point using the coordinate of the associated scores on the PCs.

Supplement Fig. 5: Metabolic trajectories of *B. pilosicoli* footprint in broth media for 120 h at a tiamulin concentration of 0.250 µg/ml. (A) PCA score plot. (B) Associated loading plot of PC1. The arrows indicate the metabolic trajectory. The metabolic trajectories described by the arrows were determined by the position of the centroids calculated at each time point using the coordinate on the associated scores on the PCs.

Supplement Tab. 1: Growth scores of *B. pilosicoli* on agar plate post-antibiotic exposure. Detection of *B. pilosicoli*'s growth 48h after plating are indicated by a sign '+' and by '-' if no growth was observed.